The Zacks Analyst Blog Highlights: TD Ameritrade Holding, Toronto-Dominion Bank, Corcept Therapeutics, Shire and Jazz Pharmaceuticals

Zacks

For Immediate Release

Chicago, IL – August 13, 2013 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the TD Ameritrade Holding Corporation (AMTD-Free Report), The Toronto-Dominion Bank (TD-Free Report), Corcept Therapeutics Inc. (CORT-Free Report), Shire (SHPG-Free Report) and Jazz Pharmaceuticals (JAZZ-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday’s Analyst Blog:

TD Ameritrade's July Trades Rise

Last week, TD Ameritrade Holding Corporation (AMTD-Free Report) – an online brokerage firm – reported a rise in average client trades from the prior year in its Activity Report for the month of Jul 2013. However, U.S. trades fell 6% from the prior month levels.


For the reported month, average client trades were 373,000, up 12% year over year. The rise in client trades largely resulted from a resurgence in the equity markets.

For the month, TD Ameritrade reported $544.2 billion in total client assets, up 21% year over year and 4% from the prior month. Moreover, average spread-based balances increased 18% year over year to $88.2 billion. Further, these balances nudged up 1% from Jun 2013.

At July-end, average fee-based balances were recorded at $120.6 billion, rising 33% year over year and 2% from the prior month.

Quarterly Performance

As of Jun 30, 2013, average client trades per day increased 12% year over year to 399,216. Net new client assets were $10.8 billion, up 11% from $9.7 billion in the past year.

At the end of June, TD Ameritrade reported total client assets worth $523.5 billion, up 18% year over year. Moreover, average spread-based balance was $84.7 billion, up 14% from $74.2 billion in the prior-year quarter. Average fee-based balance was $118.1 billion, up 34% year over year.

Our Viewpoint

Innovations in online trading, long-term investment in products and services, delivery of advanced customer service, creative as well as cost-effective marketing and sales, along with prudent expense management are the key factors behind TD Ameritrade’s strategy of boosting its trading and investing business.

Further, the company’s association with The Toronto-Dominion Bank (TD-Free Report) provides an opportunity to cross-sell its products. This is expected to be a significant growth driver for TD Ameritrade’s organic assets.

Amid a volatile operating environment, TD Ameritrade witnessed a rise in both organic client assets and trading volumes, which will benefit the company. However, a low interest rate environment and stringent regulations will likely be dampeners.

Corcept's Q2 Loss In-Line with Expectations

Corcept Therapeutics Inc. (CORT-Free Report) posted a loss per share of 11 cents in the second quarter of 2013, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 9 cents.

Corcept generated revenues of $1.9 million in the second quarter of 2013, missing the Zacks Consensus Estimate of $3.0 million. Revenues jumped 116% y/y.

The revenues reported in the quarter included a product return reserve of $0.3 million incurred due to the company's transition to a new specialty pharmacy in addition to government rebates, chargebacks and other allowances.

In Apr 2012, Corcept launched its drug, Korlym, in the U.S. Korlym, is approved in the U.S. and the EU as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adults suffering from endogenous Cushing’s syndrome, who have type II diabetes or glucose intolerance.

We note that Corcept enjoys orphan drug designation for Korlym from the FDA for the approved indication.

Selling, general and administrative expenses were $8.2 million in the second quarter of 2013, up 41.3% from the year-ago quarter. The increase was mainly due to higher staffing, consultancy and other professional services costs related to the commercialization of Korlym.

Research and development expenses in the second quarter were $4.5 million, up 24.7% in the year-ago quarter. The increase was mainly attributable to the expansion of the phase III trial on Korlym for the treatment of psychotic depression along with the development of the company’s next-generation selective GR-II antagonists.

Pipeline Update

Corcept continues to enroll patients for a phase III study on the use of Korlym for the treatment of psychotic depression. Interim results from the study are expected in the third quarter of 2014.

Corcept’s key objective in 2013 is the successful commercialization of Korlym.

Corcept currently carries a Zacks Rank #3 (Hold). Right now, Shire (SHPG-Free Report) and Jazz Pharmaceuticals (JAZZ-Free Report) are Zacks Rank #2 (Buy) stocks.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on AMTD - FREE

Get the full Report on TD - FREE

Get the full Report on CORT - FREE

Get the full Report on SHPG - FREE

Get the full Report on JAZZ - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on AMTD

Read the analyst report on TD

Read the analyst report on CORT

Read the analyst report on SHPG

Read the analyst report on JAZZ

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)